Eikon Therapeutics
Hayward, United States · Biotechnology, Health Care, Therapeutics · 390 employees
Eikon Therapeutics is advancing breakthrough therapies through the purposeful integration of science and engineering. Our proprietary discovery technologies leverage Nobel Prize-winning super-resolution microscopy, advanced engineering, and high-performance computing to visualize and measure the real-time movement of proteins in living cells, with the goal of bringing important new medicines to pe
Funding history
- Venture - Series Unknown — $350.7M — Feb 2025
- Series D — $350.7M — Feb 2025
- Venture - Series Unknown — $140.8M — Jun 2023
- Venture - Series Unknown — $517.8M — Jan 2022
- Series B — $517.8M — Jan 2022
Recent signals
- Feb 06, 2026: SEC 8-K (5.03): Eikon Therapeutics, Inc. has filed an amended and restated certificate of incorporation and amended and restated bylaws, both effective as of February 6, 2026, in connection with the closing of its initial public offering (IPO). The company's board of directors and stockholders approved these changes to be effective immediately prior to the IPO closing. This strategic move positions Eikon Therapeutics for enhanced operational governance after entering the public market, aligning its corporate structure with new business requirements and reporting standards.
- Feb 28, 2025: Raised $350.7M in Venture - Series Unknown
- Feb 26, 2025: Raised $350.7M in Series D
- Nov 20, 2024: Eikon Therapeutics Appoints Michael A. Klobuchar as Chief Operating Officer from Merck & Co. Inc.
- Jun 01, 2023: Raised $140.8M in Venture - Series Unknown
- Jan 06, 2022: Raised $517.8M in Venture - Series Unknown
- Jan 06, 2022: Raised $517.8M in Series B
- May 13, 2021: Raised $102.5M in Venture - Series Unknown
See plans & pricing → Track Eikon Therapeutics’s funding, hiring, and signals — with verified contacts — on Fundz.